
Opinion|Videos|May 3, 2024
Impact Of Durable Agents on Treatment Burden and Quality of Life in Retinal Diseases
The panel concludes its discussion with thoughts on the profound impact durable treatments have on the quality of life of patients with retinal diseases.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Bayer acquires Perfuse Therapeutics, partners with Iambic to expand ophthalmology and AI capabilities
2
Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease
3
Meta's AI glasses for veterans: Canto-Sims, OD on closing the access gap
4
Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals
5























